RE:RE:RE:RE:Corporate PresentationBearDownAZ, digitel has been holding Bioasis's feet to the fire over survival studies for a long time. To my knowledge, no study ever done by Bioasis had a survival element to it. I wouldn't think it makes sense to do one with the subject of Lockman's study, BT2111. Maybe one will have to be done with xB3-001, and maybe a tox study, I don't know.
Even if Bioasis does these studies, we may never hear about them. Maybe all we'll ever hear about are the granting of IND status, clinical trial approvals, those sorts of things. The timelines for these things are in the corporate presentation.
Meanwhile, digitel, the trader, is loading up on BTI again and is doing whatever he thinks he has to do to buy stock as cheaply as possible. Expect more (supposedly) hard questions and comments from digitel until he's pushing on the upside again.
jdstox